BioSpace News Archive

The Company will host a conference call with the investment community at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time on Tuesday, February 13, 2018.

In the study, published on January 27, 2018, researchers tracked how the cancer peptides were trafficked from the injection site to immunogenic activation in the lymph nodes

QIAGEN N.V. announced results of operations for the fourth quarter and full-year 2017, delivering on goals for adjusted net sales and adjusted earnings per share while driving the global expansion of its Sample to Insight portfolio of molecular testing solutions covering the continuum from basic research to clinical healthcare.

All the shares sold in the offering were offered by Synlogic.

Sales of $222.6 million increased 9.0% as reported and 7.9% in constant currency as compared to the fourth quarter of 2016.

Incyte announced today an update to the conference call and webcast time for its fourth quarter and year end 2017 financial results to 8:00 a.m. ET on Thursday, February 15, 2018.

The first of the studies was in rodents, next in non-human primates (monkeys), and the third in healthy human subjects.

These new sizes include additional lengths and oblique placement options with sagittally oriented lordosis.

The stock options have an exercise price of $0.38 per common share and expire ten years from the date of grant.

Nanollose is pleased to provide its Appendix 4C Cashflow Statement for the quarter ended 31 December 2017, together with the following operational update.